Kiniksa Pharmaceuticals (KNSA): 2Q26 Recap: Still underappreciated blockbuster potential; raising PT to $90

First-page research excerpt

Equity Research

29 July 2026 | 8:14AM EDT

Kiniksa Pharmaceuticals (KNSA): 2Q26 Recap: Still underappreciated

blockbuster potential; raising PT to $90

Another beat-and-raise quarter with KPL-387 advancing into pivotal

development; rethinking the relevant peer group with other long-acting drug

developers. Following another beat-and-raise result and a positive clinical update

from the Phase 2 study of KPL-387, we expect KNSA shares to continue to

outperform but note that clinical success from the latter increasingly warrants the

company being mentioned in the same breath as the YTE/long-acting mAb complex

that has also outperformed YTD. With regard to 2Q, the company reported total

revenue of $244mn, +7.7% above consensus of $226mn and +8.3% above GSe of

$225mn, driven by better-than-expected Arcalyst demand and volume growth.

Additionally, management raised FY26 revenue guidance to $980mn-$995mn from

$930mn-$950mn prior, representing a ~5% increase at the midpoint and reflecting

confidence in sustained Arcalyst demand trends through year-end. Management

attributed both the quarterly revenue outperformance and increased confidence in

the FY26 outlook to: 1) expanding prescriber breadth, with >450 new prescribers

added driving record quarterly patients enrollments, 2) increasing prescriber depth

(>150 repeat prescribers with ~29% writing prescriptions for multiple patients), 3)

meaningful remaining market opportunity, including only ~21% penetration of the

~14k-patient 2+ recurrence market and an increasingly important earlier-line

opportunity within the largely underpenetrated ~26k-patient first recurrence

population, and 4) continued improvements in patient affordability and access. We

continue to view KNSA as one of the cleanest commercial stories in our coverage

with investors frequently seeing it as a sui generis biotech in the recurrent

pericarditis market. However, we increasingly see support for the argument that it

could be considered alongside SYRE, APGE (covered by Salveen Richter), and ORKA

(not covered) with the important distinction of already having a blockbuster

commercial base. We reiterate our Buy rating and raise our 12-months price

…